Title: Imaging Response After Unconfirmed Progression: Data Trends from Clinical Trials Utilizing iRECIST
Date: Wednesday, March 16th, 2022
Time: 1:20 p.m. – 1:35 p.m. EST
Location: Track A
The iRECIST approach is primarily focused on confirmation of radiographic disease progression in the setting of immunotherapy. With the unique ability to look across multiple studies and indications, this discussion shares data trends from iRECIST trials in the context of confirmed and unconfirmed progressive disease.
Advisor of Medical and Scientific Affairs at Clario
Jack’s focus is in support of the oncology therapeutic area where he provides input on trial design, review methodology and development of operational strategies for new imaging criteria. His expertise extends to optimization of imaging documentation and creation of workflows for novel image analysis approaches. Prior to positions with various CROs, Dr. Skinner worked at the National Comprehensive Cancer Network where he developed the NCCN Imaging Appropriate Use Criteria. Dr. Skinner earned his PhD in Biomedical Engineering from Vanderbilt University. His post-doctoral research focused on the development of advanced MRI techniques for evaluating late stage brain cancer.